FAQ

Bath Cancer Research DiSC assay for CLL endorsed by US government panel

If you are a patient, please read.......
The median isn’t the message.

Click here if you have problems opening Request Form

Click here for a colourful resumé of the work of Bath Cancer Research (2.4MB)

Cliquez ici pour nos lecteurs Français qui désirent plus d'information

Research
Scientists at Bath Cancer Research undertake ex vivo drug sensitivity studies using the TRAC assay (Tumour Response to Anti-neoplastic Compounds, a development of the DiSC assay [Ref. 10 of Selected Publications]). With this we assess the cytotoxic drug sensitivity of fresh human cells from patients with leukaemia and lymphoma. Our greatest expertise is with chronic lymphocytic leukaemia (CLL), acute myeloid leukaemia (AML or ANLL), non-Hodgkin's lymphoma (NHL) and similar diseases.

New Drug Screening
Bath Cancer Research tests new cytotoxic agents in "Ex vivo Phase II trials" (Ref 14 of Selected Publications]. A new drug is tested against tumour cells from a variety of diseases as well as normal cells. This can elucidate targets for further clinical Phase II or Phase III trials, provide information about cross-resistance with known cytotoxic drugs and produce an ex vivo therapeutic index.

Individualised Tumor Response Testing (ITRT) pages click here

Suggestions, comments and queries for Bath Cancer Research

© Bath Cancer Research 2000-2008

Date last modified: 26/3/08.

Webmaster: webmaster@caltri.org

[Home]